Similar articles

• Effect of dopamine and neuroleptics on plasma growth hormone and prolactin in normal men.

  Langer G, Sachar EJ, Halpern FS. Langer G, et al. Psychoneuroendocrinology. 1978 Apr;3(2):165-9. doi: 10.1016/0306-4530(78)90004-5. Psychoneuroendocrinology. 1978. PMID: 704750 No abstract available.
• Multiphasic prolactin release and mammary development in virgin rats after prolonged treatment with perphenazine or perphenazine sulphoxide.

  Shani J, Givant Y, Goldhaber G, Sulman FG. Shani J, et al. J Endocrinol. 1976 Aug;70(2):311-2. doi: 10.1677/joe.0.0700311. J Endocrinol. 1976. PMID: 965888 No abstract available.
• Modification of the receptor component of adenylate cyclase in the rat brain by phenothiazine derivatives.

  Palmer GC, Manian AA. Palmer GC, et al. Neuropharmacology. 1974 Sep;13(9):851-66. doi: 10.1016/0028-3908(74)90041-0. Neuropharmacology. 1974. PMID: 4154419 No abstract available.
• The role of vasoactive intestinal polypeptide (VIP) as a hypothalamic neurohormone.

  Nicosia S, Oliva D, Giannattasio G, Spada A. Nicosia S, et al. J Endocrinol Invest. 1983 Jun;6(3):235-42. doi: 10.1007/BF03350614. J Endocrinol Invest. 1983. PMID: 6311891 Review. No abstract available.
• The mechanisms by which vasoactive intestinal peptide (VIP) and thyrotropin releasing hormone (TRH) stimulate prolactin release from pituitary cells.

  Bjøro T, Sand O, Ostberg BC, Gordeladze JO, Torjesen P, Gautvik KM, Haug E. Bjøro T, et al. Biosci Rep. 1990 Apr;10(2):189-99. doi: 10.1007/BF01116578. Biosci Rep. 1990. PMID: 2162702 Review.